| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Radio Frequency Identification Device | 2 | 2019 | 14 | 0.87 | Why? |
| Antitubercular Agents | 2 | 2017 | 775 | 0.83 | Why? |
| Islam | 4 | 2016 | 545 | 0.82 | Why? |
| Hand Hygiene | 4 | 2021 | 1493 | 0.82 | Why? |
| Acinetobacter | 1 | 2018 | 58 | 0.75 | Why? |
| Histoplasmosis | 1 | 2018 | 83 | 0.70 | Why? |
| Fecal Microbiota Transplantation | 3 | 2018 | 372 | 0.68 | Why? |
| Amikacin | 1 | 2017 | 62 | 0.67 | Why? |
| France | 29 | 2021 | 12074 | 0.67 | Why? |
| Tetanus | 1 | 2017 | 61 | 0.66 | Why? |
| Immunocompetence | 1 | 2018 | 280 | 0.66 | Why? |
| Extensively Drug-Resistant Tuberculosis | 1 | 2017 | 87 | 0.63 | Why? |
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2018 | 214 | 0.61 | Why? |
| Microbiology | 1 | 2018 | 134 | 0.60 | Why? |
| Travel | 10 | 2020 | 7220 | 0.56 | Why? |
| Guideline Adherence | 5 | 2021 | 2309 | 0.55 | Why? |
| Hospital Design and Construction | 1 | 2017 | 287 | 0.55 | Why? |
| Homeless Persons | 4 | 2018 | 1171 | 0.54 | Why? |
| Behavior Therapy | 1 | 2017 | 235 | 0.52 | Why? |
| Drug Synergism | 1 | 2017 | 833 | 0.52 | Why? |
| Mycobacterium | 1 | 2014 | 143 | 0.50 | Why? |
| Enterobacteriaceae Infections | 1 | 2018 | 529 | 0.49 | Why? |
| Lice Infestations | 2 | 2017 | 39 | 0.48 | Why? |
| Cross Infection | 4 | 2021 | 8675 | 0.47 | Why? |
| Tuberculosis, Multidrug-Resistant | 1 | 2017 | 433 | 0.46 | Why? |
| Nasal Cavity | 2 | 2014 | 909 | 0.44 | Why? |
| Nose | 2 | 2020 | 1093 | 0.43 | Why? |
| Travel-Related Illness | 1 | 2018 | 1357 | 0.42 | Why? |
| Mentoring | 1 | 2017 | 432 | 0.42 | Why? |
| Hand Disinfection | 2 | 2017 | 1671 | 0.42 | Why? |
| Respiratory Tract Infections | 7 | 2018 | 6817 | 0.41 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 2018 | 2309 | 0.39 | Why? |
| Azithromycin | 6 | 2021 | 3943 | 0.38 | Why? |
| Communicable Diseases | 3 | 2018 | 2148 | 0.36 | Why? |
| Mycobacterium tuberculosis | 1 | 2017 | 1164 | 0.34 | Why? |
| Health Status Indicators | 1 | 2009 | 341 | 0.31 | Why? |
| Housing | 1 | 2014 | 1146 | 0.30 | Why? |
| Hypoxia | 1 | 2020 | 3626 | 0.30 | Why? |
| Infection Control | 5 | 2021 | 23131 | 0.29 | Why? |
| Gastrointestinal Microbiome | 1 | 2018 | 1961 | 0.29 | Why? |
| Health Personnel | 5 | 2021 | 29646 | 0.29 | Why? |
| Viruses | 3 | 2018 | 2238 | 0.29 | Why? |
| Carrier State | 2 | 2014 | 2100 | 0.28 | Why? |
| RNA Viruses | 1 | 2012 | 824 | 0.28 | Why? |
| Scabies | 1 | 2005 | 75 | 0.28 | Why? |
| Evidence-Based Medicine | 1 | 2018 | 3228 | 0.28 | Why? |
| Disease Reservoirs | 1 | 2014 | 1672 | 0.28 | Why? |
| World Health Organization | 1 | 2017 | 4213 | 0.27 | Why? |
| Skin Diseases, Infectious | 1 | 2005 | 77 | 0.27 | Why? |
| Respiratory Tract Diseases | 1 | 2012 | 1061 | 0.26 | Why? |
| Chaperonins | 1 | 2002 | 11 | 0.26 | Why? |
| Citrate (si)-Synthase | 1 | 2002 | 10 | 0.26 | Why? |
| Anaplasma | 1 | 2002 | 8 | 0.26 | Why? |
| Travel Medicine | 2 | 2019 | 335 | 0.26 | Why? |
| Hospitals | 3 | 2017 | 11793 | 0.25 | Why? |
| Disinfection | 1 | 2017 | 2912 | 0.25 | Why? |
| Ehrlichiosis | 1 | 2002 | 18 | 0.25 | Why? |
| Influenza, Human | 4 | 2016 | 10779 | 0.24 | Why? |
| Hydroxychloroquine | 6 | 2021 | 12447 | 0.23 | Why? |
| Universities | 1 | 2017 | 4374 | 0.23 | Why? |
| Respiratory System | 1 | 2014 | 3213 | 0.23 | Why? |
| Sputum | 3 | 2020 | 1720 | 0.22 | Why? |
| Saudi Arabia | 6 | 2016 | 4423 | 0.22 | Why? |
| Fluorescent Antibody Technique, Indirect | 2 | 2020 | 393 | 0.20 | Why? |
| Influenza A Virus, H1N1 Subtype | 1 | 2014 | 2984 | 0.20 | Why? |
| Drug Resistance, Multiple, Bacterial | 2 | 2018 | 1115 | 0.20 | Why? |
| Angiotensin I | 1 | 2021 | 200 | 0.19 | Why? |
| Fluorine Radioisotopes | 1 | 2018 | 59 | 0.19 | Why? |
| Histoplasma | 1 | 2018 | 42 | 0.19 | Why? |
| Genotype | 3 | 2021 | 4697 | 0.19 | Why? |
| Coronavirus | 7 | 2020 | 18339 | 0.19 | Why? |
| Attitude of Health Personnel | 1 | 2017 | 4741 | 0.18 | Why? |
| Adult | 34 | 2021 | 244371 | 0.18 | Why? |
| Medical Office Buildings | 1 | 2017 | 14 | 0.18 | Why? |
| Pediculus | 1 | 2017 | 35 | 0.18 | Why? |
| Roma | 1 | 2018 | 61 | 0.18 | Why? |
| Male | 37 | 2021 | 367725 | 0.18 | Why? |
| Immunocompromised Host | 1 | 2014 | 5150 | 0.17 | Why? |
| Humans | 61 | 2021 | 930598 | 0.17 | Why? |
| Middle Aged | 31 | 2021 | 270681 | 0.17 | Why? |
| Female | 37 | 2021 | 380317 | 0.17 | Why? |
| Phenothiazines | 1 | 2017 | 50 | 0.17 | Why? |
| Itraconazole | 1 | 2018 | 135 | 0.17 | Why? |
| Bacteria | 2 | 2014 | 1897 | 0.17 | Why? |
| Anti-Bacterial Agents | 4 | 2021 | 10083 | 0.16 | Why? |
| Clofazimine | 1 | 2017 | 85 | 0.16 | Why? |
| Antibodies, Bacterial | 2 | 2017 | 510 | 0.16 | Why? |
| Drug Resistance, Bacterial | 1 | 2006 | 1414 | 0.16 | Why? |
| Hemorrhagic Fever, Ebola | 2 | 2018 | 1475 | 0.16 | Why? |
| West Nile Fever | 1 | 2019 | 166 | 0.16 | Why? |
| Aged, 80 and over | 18 | 2021 | 88759 | 0.16 | Why? |
| Clarithromycin | 1 | 2017 | 112 | 0.16 | Why? |
| Minocycline | 1 | 2017 | 101 | 0.16 | Why? |
| Coronavirus Infections | 19 | 2020 | 253789 | 0.15 | Why? |
| Health Status | 1 | 2009 | 3259 | 0.15 | Why? |
| Young Adult | 15 | 2021 | 93724 | 0.15 | Why? |
| HIV Integrase Inhibitors | 1 | 2017 | 173 | 0.15 | Why? |
| Angiotensin II | 1 | 2021 | 601 | 0.15 | Why? |
| Aged | 21 | 2021 | 215776 | 0.14 | Why? |
| Health Knowledge, Attitudes, Practice | 2 | 2018 | 8811 | 0.14 | Why? |
| Injections, Intramuscular | 1 | 2017 | 800 | 0.14 | Why? |
| Heterocyclic Compounds, 3-Ring | 1 | 2017 | 275 | 0.14 | Why? |
| Biotechnology | 1 | 2017 | 444 | 0.13 | Why? |
| Clostridium Infections | 2 | 2018 | 595 | 0.13 | Why? |
| Inventions | 1 | 2017 | 372 | 0.13 | Why? |
| Bacterial Proteins | 1 | 2002 | 1318 | 0.13 | Why? |
| Zinc | 1 | 2021 | 817 | 0.13 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2020 | 13720 | 0.12 | Why? |
| Bacterial Infections | 1 | 2006 | 2229 | 0.12 | Why? |
| Quarantine | 1 | 2020 | 18418 | 0.12 | Why? |
| Lymphadenopathy | 1 | 2018 | 444 | 0.12 | Why? |
| Milk | 1 | 2013 | 158 | 0.12 | Why? |
| Pharynx | 1 | 2020 | 1544 | 0.12 | Why? |
| Weight Gain | 1 | 2017 | 552 | 0.12 | Why? |
| Drug Resistance, Viral | 1 | 2018 | 1083 | 0.11 | Why? |
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2019 | 1316 | 0.11 | Why? |
| Containment of Biohazards | 1 | 2017 | 762 | 0.11 | Why? |
| Antiviral Agents | 6 | 2021 | 41703 | 0.11 | Why? |
| Pericarditis | 1 | 2016 | 417 | 0.11 | Why? |
| Adolescent | 12 | 2021 | 86841 | 0.11 | Why? |
| Metapneumovirus | 1 | 2014 | 465 | 0.11 | Why? |
| Asymptomatic Diseases | 2 | 2020 | 3444 | 0.11 | Why? |
| Rickettsia Infections | 2 | 2009 | 58 | 0.11 | Why? |
| Measles | 1 | 2018 | 608 | 0.11 | Why? |
| Video Recording | 1 | 2017 | 786 | 0.10 | Why? |
| Peptide Fragments | 1 | 2021 | 2075 | 0.10 | Why? |
| Exanthema | 1 | 2020 | 1097 | 0.10 | Why? |
| Sentinel Surveillance | 1 | 2018 | 1093 | 0.10 | Why? |
| Dermacentor | 1 | 2009 | 9 | 0.10 | Why? |
| Enterovirus | 1 | 2014 | 402 | 0.10 | Why? |
| Pneumonia, Viral | 12 | 2020 | 243684 | 0.10 | Why? |
| Respiratory Syncytial Viruses | 1 | 2014 | 612 | 0.10 | Why? |
| Ribavirin | 1 | 2017 | 1182 | 0.10 | Why? |
| Immunization, Secondary | 1 | 2017 | 1649 | 0.10 | Why? |
| Dengue Virus | 1 | 2016 | 910 | 0.10 | Why? |
| Mass Spectrometry | 1 | 2014 | 1165 | 0.09 | Why? |
| Antimicrobial Stewardship | 1 | 2017 | 931 | 0.09 | Why? |
| Drug Therapy, Combination | 5 | 2021 | 7268 | 0.09 | Why? |
| Disease Outbreaks | 4 | 2019 | 27595 | 0.09 | Why? |
| Thorax | 1 | 2018 | 1873 | 0.09 | Why? |
| Middle East | 1 | 2013 | 1418 | 0.09 | Why? |
| Treatment Outcome | 7 | 2021 | 51732 | 0.09 | Why? |
| Child | 8 | 2020 | 70012 | 0.09 | Why? |
| Retrospective Studies | 9 | 2020 | 105322 | 0.09 | Why? |
| Fever | 3 | 2020 | 7795 | 0.09 | Why? |
| Dietary Supplements | 1 | 2021 | 2251 | 0.09 | Why? |
| Sulfonamides | 1 | 2017 | 1294 | 0.09 | Why? |
| Africa, Northern | 1 | 2009 | 539 | 0.09 | Why? |
| Antifungal Agents | 1 | 2018 | 1828 | 0.09 | Why? |
| Rhinovirus | 1 | 2014 | 979 | 0.09 | Why? |
| Coxiella burnetii | 2 | 2017 | 120 | 0.08 | Why? |
| Viral Load | 4 | 2020 | 15850 | 0.08 | Why? |
| Child, Preschool | 6 | 2020 | 36283 | 0.08 | Why? |
| Betacoronavirus | 12 | 2020 | 204454 | 0.08 | Why? |
| Hepatitis C, Chronic | 1 | 2017 | 973 | 0.08 | Why? |
| Diagnosis, Differential | 2 | 2020 | 7220 | 0.08 | Why? |
| Real-Time Polymerase Chain Reaction | 2 | 2020 | 11367 | 0.08 | Why? |
| Dyspnea | 1 | 2020 | 3847 | 0.08 | Why? |
| Hepatitis C | 2 | 2017 | 1514 | 0.08 | Why? |
| Crowding | 1 | 2013 | 731 | 0.08 | Why? |
| Tinea Pedis | 1 | 2005 | 6 | 0.08 | Why? |
| Prevalence | 6 | 2020 | 25773 | 0.08 | Why? |
| Impetigo | 1 | 2005 | 18 | 0.08 | Why? |
| Clinical Laboratory Techniques | 4 | 2020 | 23402 | 0.08 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 3 | 2017 | 8843 | 0.08 | Why? |
| Anti-Infective Agents | 1 | 2018 | 1766 | 0.08 | Why? |
| Polymerase Chain Reaction | 4 | 2020 | 6740 | 0.07 | Why? |
| Orthomyxoviridae | 1 | 2014 | 1168 | 0.07 | Why? |
| Infant | 5 | 2020 | 30274 | 0.07 | Why? |
| Camelus | 1 | 2013 | 1425 | 0.07 | Why? |
| Hospitals, University | 1 | 2017 | 4173 | 0.07 | Why? |
| Tomography, X-Ray Computed | 3 | 2020 | 25144 | 0.07 | Why? |
| Case-Control Studies | 2 | 2018 | 17671 | 0.07 | Why? |
| Rickettsia | 2 | 2009 | 101 | 0.07 | Why? |
| Interviews as Topic | 1 | 2013 | 1952 | 0.07 | Why? |
| Dengue | 1 | 2016 | 1565 | 0.07 | Why? |
| Intensive Care Units | 2 | 2021 | 29594 | 0.07 | Why? |
| SARS Virus | 2 | 2020 | 13021 | 0.07 | Why? |
| Zika Virus | 1 | 2016 | 1924 | 0.06 | Why? |
| Phylogeny | 1 | 2002 | 13341 | 0.06 | Why? |
| Symptom Assessment | 2 | 2016 | 4967 | 0.06 | Why? |
| Pruritus | 1 | 2005 | 215 | 0.06 | Why? |
| Urban Population | 1 | 2014 | 2000 | 0.06 | Why? |
| Public Health Surveillance | 2 | 2014 | 3129 | 0.06 | Why? |
| HIV-1 | 1 | 2018 | 3365 | 0.06 | Why? |
| Prospective Studies | 5 | 2021 | 43301 | 0.06 | Why? |
| Zika Virus Infection | 1 | 2016 | 1920 | 0.06 | Why? |
| HIV Infections | 3 | 2018 | 11620 | 0.06 | Why? |
| Severity of Illness Index | 5 | 2021 | 48226 | 0.06 | Why? |
| Follow-Up Studies | 2 | 2020 | 17020 | 0.06 | Why? |
| Health Surveys | 1 | 2013 | 2841 | 0.06 | Why? |
| Infant, Newborn | 2 | 2020 | 23105 | 0.06 | Why? |
| Cough | 2 | 2020 | 4891 | 0.06 | Why? |
| Communicable Disease Control | 3 | 2017 | 29620 | 0.06 | Why? |
| Seasons | 1 | 2014 | 4071 | 0.05 | Why? |
| Brazil | 1 | 2018 | 12582 | 0.05 | Why? |
| Time-to-Treatment | 1 | 2018 | 5883 | 0.05 | Why? |
| Virus Diseases | 1 | 2018 | 3779 | 0.05 | Why? |
| Europe | 1 | 2017 | 12702 | 0.05 | Why? |
| Communicable Diseases, Emerging | 1 | 2014 | 2523 | 0.05 | Why? |
| Age Distribution | 1 | 2009 | 3567 | 0.05 | Why? |
| Rickettsia conorii | 1 | 1998 | 7 | 0.05 | Why? |
| Time Factors | 3 | 2020 | 31397 | 0.05 | Why? |
| Rickettsia typhi | 1 | 1998 | 7 | 0.05 | Why? |
| Q Fever | 2 | 2017 | 130 | 0.05 | Why? |
| Animals | 8 | 2019 | 78931 | 0.05 | Why? |
| Disease Management | 1 | 2017 | 6841 | 0.05 | Why? |
| RNA, Ribosomal, 16S | 1 | 2002 | 793 | 0.05 | Why? |
| Students | 1 | 2017 | 5255 | 0.05 | Why? |
| HLA-DR Antigens | 1 | 2021 | 563 | 0.05 | Why? |
| Pilot Projects | 2 | 2021 | 5182 | 0.05 | Why? |
| Lipopolysaccharide Receptors | 1 | 2021 | 357 | 0.05 | Why? |
| Ribotyping | 1 | 2018 | 54 | 0.05 | Why? |
| Health Behavior | 1 | 2017 | 4449 | 0.05 | Why? |
| Multivariate Analysis | 1 | 2009 | 5440 | 0.05 | Why? |
| Boutonneuse Fever | 2 | 1998 | 21 | 0.04 | Why? |
| Enterocolitis, Pseudomembranous | 1 | 2018 | 93 | 0.04 | Why? |
| West Indies | 1 | 2016 | 48 | 0.04 | Why? |
| West Nile virus | 1 | 2019 | 206 | 0.04 | Why? |
| Statistics, Nonparametric | 1 | 2020 | 1008 | 0.04 | Why? |
| Epidemics | 1 | 2017 | 6407 | 0.04 | Why? |
| Horses | 1 | 2019 | 474 | 0.04 | Why? |
| Measles virus | 1 | 2018 | 194 | 0.04 | Why? |
| Molecular Sequence Data | 1 | 2002 | 3198 | 0.04 | Why? |
| Respiratory Rate | 1 | 2020 | 691 | 0.04 | Why? |
| Dogs | 2 | 2002 | 2529 | 0.04 | Why? |
| Pandemics | 12 | 2021 | 389249 | 0.04 | Why? |
| Burkina Faso | 1 | 2016 | 302 | 0.04 | Why? |
| Odds Ratio | 2 | 2018 | 5861 | 0.04 | Why? |
| Oxazines | 1 | 2017 | 279 | 0.04 | Why? |
| Risk | 2 | 2018 | 5288 | 0.04 | Why? |
| Survival Analysis | 2 | 2020 | 7592 | 0.04 | Why? |
| Chloroquine | 2 | 2021 | 3152 | 0.04 | Why? |
| Measles Vaccine | 1 | 2018 | 301 | 0.04 | Why? |
| Vaccination | 2 | 2018 | 19050 | 0.04 | Why? |
| Chronic Disease | 1 | 2009 | 5139 | 0.04 | Why? |
| Coinfection | 1 | 2014 | 6820 | 0.03 | Why? |
| Incidence | 3 | 2020 | 25622 | 0.03 | Why? |
| Piperazines | 1 | 2017 | 445 | 0.03 | Why? |
| Surveys and Questionnaires | 4 | 2019 | 43792 | 0.03 | Why? |
| Global Health | 1 | 2017 | 13911 | 0.03 | Why? |
| Drug Interactions | 1 | 2021 | 1653 | 0.03 | Why? |
| Tobacco Smoking | 1 | 2017 | 349 | 0.03 | Why? |
| Influenza Vaccines | 1 | 2009 | 2941 | 0.03 | Why? |
| Lung | 2 | 2020 | 31049 | 0.03 | Why? |
| Risk Factors | 5 | 2020 | 71621 | 0.03 | Why? |
| Endocarditis, Bacterial | 1 | 2017 | 344 | 0.03 | Why? |
| RNA, Viral | 1 | 2020 | 32276 | 0.03 | Why? |
| Pyridones | 1 | 2017 | 738 | 0.03 | Why? |
| Dose-Response Relationship, Drug | 1 | 2021 | 3776 | 0.03 | Why? |
| Recombination, Genetic | 1 | 2018 | 1265 | 0.03 | Why? |
| Smell | 1 | 2020 | 1851 | 0.03 | Why? |
| Religion | 1 | 2014 | 353 | 0.03 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2014 | 12361 | 0.03 | Why? |
| Latin America | 1 | 2016 | 1721 | 0.03 | Why? |
| Nasopharynx | 2 | 2020 | 10224 | 0.03 | Why? |
| Disease Transmission, Infectious | 1 | 2014 | 9044 | 0.03 | Why? |
| Administration, Oral | 1 | 2017 | 2340 | 0.03 | Why? |
| Gene Expression Profiling | 1 | 2021 | 3788 | 0.02 | Why? |
| Africa | 1 | 2018 | 2986 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2018 | 2830 | 0.02 | Why? |
| Scalp | 1 | 2009 | 82 | 0.02 | Why? |
| Monocytes | 1 | 2021 | 2978 | 0.02 | Why? |
| Bites and Stings | 1 | 2009 | 91 | 0.02 | Why? |
| Mexico | 1 | 2016 | 2787 | 0.02 | Why? |
| Antibodies, Viral | 1 | 2020 | 51949 | 0.02 | Why? |
| Recurrence | 1 | 2018 | 3675 | 0.02 | Why? |
| Age Factors | 2 | 2020 | 21039 | 0.02 | Why? |
| History, 21st Century | 1 | 2014 | 1849 | 0.02 | Why? |
| Hepacivirus | 1 | 2017 | 1509 | 0.02 | Why? |
| Cohort Studies | 3 | 2017 | 36005 | 0.02 | Why? |
| RNA, Messenger | 1 | 2021 | 5131 | 0.02 | Why? |
| Climate | 1 | 1992 | 557 | 0.02 | Why? |
| Clinical Protocols | 1 | 2017 | 2734 | 0.02 | Why? |
| Alcohol Drinking | 1 | 2017 | 1663 | 0.02 | Why? |
| Occupational Diseases | 1 | 2021 | 2787 | 0.02 | Why? |
| Anti-HIV Agents | 1 | 2018 | 2209 | 0.02 | Why? |
| Liver Cirrhosis | 1 | 2017 | 1810 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 7868 | 0.02 | Why? |
| Virus Shedding | 1 | 2021 | 5834 | 0.02 | Why? |
| Feces | 1 | 2018 | 4235 | 0.02 | Why? |
| Referral and Consultation | 1 | 2020 | 4816 | 0.02 | Why? |
| Adenosine Monophosphate | 1 | 2020 | 5652 | 0.01 | Why? |
| Alanine | 1 | 2020 | 5687 | 0.01 | Why? |
| Societies, Medical | 1 | 2017 | 6907 | 0.01 | Why? |
| Mauritania | 1 | 1998 | 39 | 0.01 | Why? |
| Cross-Sectional Studies | 2 | 2018 | 53120 | 0.01 | Why? |
| Typhus, Endemic Flea-Borne | 1 | 1998 | 25 | 0.01 | Why? |
| Mutation | 1 | 2018 | 12376 | 0.01 | Why? |
| Skin | 1 | 2009 | 2096 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2020 | 21571 | 0.01 | Why? |
| Rural Health | 1 | 1992 | 243 | 0.01 | Why? |
| Hospitalization | 2 | 2018 | 54280 | 0.01 | Why? |
| Blood Donors | 1 | 1998 | 2956 | 0.00 | Why? |
| Seroepidemiologic Studies | 1 | 1998 | 10017 | 0.00 | Why? |